Understanding the evolutionary mechanisms and genomic events leading to castration-resistant (CR) prostate cancer (PC) is key to improve the outcome of this otherwise deadly disease. Here, we delineated the tumour history of seven patients progressing to castration resistance by analysing matched prostate cancer tissues before and after castration. We performed genomic profiling of DNA content-based flow-sorted populations in order to define the different evolutionary patterns. In one patient, we discovered that a catastrophic genomic event, known as chromothripsis, resulted in multiple CRPC tumour populations with distinct, potentially advantageous copy number aberrations, including an amplification of FK506 binding protein 4 (FKBP4, also known as FKBP52), a protein enhancing the transcriptional activity of androgen receptor signalling. Analysis of FKBP4 protein expression in more than 500 prostate cancer samples revealed increased expression in CRPC in comparison to hormone-naïve (HN) PC. Moreover, elevated FKBP4 expression was associated with poor survival of patients with HNPC. We propose FKBP4 amplification and overexpression as a selective advantage in the process of tumour evolution and as a potential mechanism associated with the development of CRPC. Furthermore, FKBP4 interaction with androgen receptor may provide a potential therapeutic target in PC.
Introduction
Prostate cancer (PC) is the most frequently diagnosed cancer among males in developed countries and the third leading cause of cancer-related death in men [1, 2] . The long disease course requires different treatment modalities [3, 4] . Aside from surgery and radiotherapy, androgen deprivation therapy (ADT) is one of PC's treatment pillars. Despite an initial clinical response, patients relapse after a median time of about 11.2 months [5] , with castration resistance (CR) and progressive disease [6, 7] . The resistance to ADT in PC exemplifies the selective pressure exerted by medical treatment on tumours and highlights their ability for adaptive changes, referred to as tumour evolution [8] [9] [10] . According to conventional evolutionary theory, multiple lineages of tumour cell populations can lead to intratumoural heterogeneity, a phenomenon abundant in PC [11] . The deconvolution of the resulting clonal mixtures poses a major challenge even with high-definition genomic tools, including array comparative genomic hybridisation (aCGH) and next-generation sequencing (NGS) [12] . In previous studies, we demonstrated the feasibility of DNA content-based flow-sorting followed by genomic profiling of tumour cell populations to determine the clonal composition of different tumour types and the resulting intratumoural genomic heterogeneity [8, 13] . For this study, we analysed seven patients with multiple time points of PC biopsies, each with at least one biopsy under ADT. We combined DNA copy number analysis and whole-exome sequencing to investigate the patient-specific evolutionary patterns arising under the selective pressure of ADT.
Materials and methods

Clinical samples
This study was approved by the Ethics Committee of Northwestern and Central Switzerland (EKNZ, No EK13/11). Patient characteristics are given in Table 1 . All samples used in this study were collected for clinical (diagnostic) purposes from patients who underwent transurethral resection or radical prostatectomy due to clinical symptoms such as urinary obstruction or in a curative attempt. Samples were collected in liquid nitrogen and stored at −80 ∘ C. Surplus tumour tissue is routinely collected in liquid nitrogen at our institution if enough tissue from the same specimen is available for formalin fixation and diagnostics. Samples complying with the inclusion criteria -(i) histologically diagnosed PC, (ii) multiple biopsies and/or time points available, (iii) concurrent ADT, and (iv) sufficient quality and amount of material -were carefully selected by an experienced pathologist (LB). Both TMAs used in this study (crTMA and the prostate progression TMA) were manufactured as previously described [14, 15] .
Flow cytometry and aCGH microarrays
Biopsies were minced in NST buffer containing 146 mM NaCl, 10 mM Tris-HCl (pH 7.5), 0.2% Nonidet P40, and DAPI according to published protocols [8, 13] . Nuclei were disaggregated and then filtered through a 40-μm mesh before flow sorting with an Influx cytometer (Becton-Dickinson, Allschwil, Switzerland) with UV excitation and DAPI emission collected at >450 nm. DNA content and cell cycle were analysed using the software program MultiCycle (Phoenix Flow Systems, San Diego, CA, USA) and R [16] . For aCGH analyses, the Agilent microarray platform (Agilent Technologies, Santa Clara, CA, USA) was used as previously described [8] . All microarray files and metadata have been deposited in NCBI's Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE108203 (https://www.ncbi.nlm .nih.gov/geo/query/acc.cgi?acc=GSE108203). ACGH data analysis was performed using the Limma package [17] in the R environment [16] . Segment calling was performed with the circular binary segmentation (CBS) algorithm [18, 19] . Segments with a log 2 ratio higher than 0.58 (upper boundary) or lower than −1.0 (lower boundary) were defined as genomic aberrations.
Genomic analysis
DNA was extracted using Qiagen micro kits (Qiagen, Hilden, Germany). For each hybridisation, 100 ng of genomic DNA from each sample and of pooled commercial 46,XX or 46,XY reference (Promega, Madison, WI, USA) were amplified using the GenomiPhi amplification kit (GE Healthcare, Little Chalfont, UK). One microgram of amplified sample and 1 μg of amplified reference template were digested with DNaseI and then labelled with Cy-5 dUTP and Cy-3 dUTP using a BioPrime labelling kit (Invitrogen, Carlsbad, CA, USA). All labelling reactions were assessed using Nanodrop before mixing and hybridisation to either 244 000 or 400 000 feature CGH arrays (Agilent Technologies). Whole-exome paired-end sequencing on a HiSeq 2000 (Illumina Inc, San Diego, CA, USA) was performed after exome capturing using the Agilent Sure Select enrichment system (Agilent Technologies). Resulting bam files were uploaded to Five3 Genomics (Santa Cruz, CA, USA) and processed according to their protocol (Five3 Genomics). In brief, the human genome reference build 37 (hg19) was used to align the data with BWA [20] . In turn, duplicates were marked by samblaster [21] and indel realignment and base quality recalibration were performed by GATK v2.3 [22] . Due to missing germline DNA as a reference, exome sequencing data were only used for determining structural variants. Structural variants were identified using methods described on structural variation in glioblastoma multiforme tumours using the BamBam algorithm [23, 24] . They were required to have a minimum support of at least six reads, with an average mapping quality greater than 30.
IHC and FISH of FKBP4
FKBP4 staining was performed with the mouse monoclonal antibody AT4D3 (LS-C103478; LifeSpan Biosciences, Seattle, WA, USA) in a 1:800 dilution, and p53 staining with the mouse monoclonal antibody DO-7 (800-2912; Ventana, Tucson, AZ, USA), both on a Ventana Benchmark XI instrument (Ventana), according to standard indirect immunoperoxidase procedures. FKBP4 custom FISH probes were created according to published protocols [25, 26] by use of the BAC clone RP11-958H19 (Empire Genomics, Buffalo, NY, USA). As a reference, a SpectrumGreen-labelled chromosome 12 centromeric probe was used (Vysis Abbott Molecular, Abbott Park, IL, USA).
Cell culture experiments
The BPH cell line was acquired from the American Type Culture Collection (ATCC, Manassas, VA, USA). Media were supplemented with 20% heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin/streptomycin, 20 ng/ml testosterone (Sigma Aldrich, St Louis, MO, USA), and 1× Insulin-Transferrin-Selenium Supplement Mix (Thermo Fisher Scientific, Waltham, MA, USA). Cells were transfected with Lipofectamine LTX and Plus76 JR Federer-Gsponer et al was assessed using the xCELLigence system (ACEA Biosciences, San Diego, CA, USA). Twenty-four hours after transfection, cells were washed twice with PBS and resuspended in DMEM without Phenol Red supplemented with charcoal-stripped FBS (Thermo Fisher Scientific) with or without testosterone (70 nM). Five thousand cells per well were plated in an 18-well plate and the growth rate was measured in real time at the indicated time points.
Statistics
Differences between two groups were analysed with the Wilcoxon's rank sum test or Student's t-test for in vitro experiments. Correlations were tested according to Spearman. Survival curves were plotted by the Kaplan-Meier method and differences were assessed using the log-rank test. P values less than 0.05 were considered significant. Pearson's correlation was used to assess array similarity and evolutionary distance.
Results
Heterogeneous nature of clonal cancer evolution under the selective pressure of androgen deprivation therapy
The clinical data and pathological information of the patients and the corresponding biopsies are summarised in Table 1 . The genomic data from patient A have been described in a previous study (see above and ref 8): in the observed branched evolutionary pattern, one diploid tumour population represented the trunk of the tumour lineage with a gradual evolution of aneuploid branches under the selective pressure of ADT.
This lineage gave rise to morphologically less differentiated and genomically more aberrant tumour populations that were eliminated by therapeutic escalations ( Figure 1A ). As in our previous study, we applied DAPI-based flow-sorting followed by genomic profiling by array CGH (aCGH) of all, and exome sequencing of selected, sorted populations [8, 13] . Tumour populations were defined by DNA content (± 0.2 N) and by the presence of aberrant genomic intervals detected by aCGH. We identified three evolutionary patterns under ADT that were congruent with conventional evolutionary theory and NGS-based cancer models [9, 27, 28] ( Table 1 , Figure 1A -C, and supplementary material, Figure S1 ): (i) linear evolution with gradual acquisition of genomic aberrations ( Figure 1B and supplementary material, Figure S1 ), as well as (ii) branched evolution with (iia) gradual ( Figure 1A , C) or (iib) punctual ( Figure 1D ) acquisition of genomic aberrations. Whereas in gradual evolution few events (here: genomic aberrations) are slowly acquired over time, a punctual evolution ( Figure 1D ) represents the occurrence of multiple decisive events in a single or at least short time frame with a mostly quiescent evolution in between [27] . In contrast to the evolutionary pattern of the patient introduced in our previous study ( Figure 1A ), a linear rather than a branched evolution was found in most patients under ADT (four out of seven). In this predominant pattern, a stable but genomically aberrant tumour population acquired new genomic aberrations without evident generation of a stable parallel tumour population. The ploidy remained constant (up to 2 years), and the low number of newly acquired copy number aberrations (CNAs) after therapy initiation advocated for a gradual evolution. For example, the copy number variations within the 3.7 N population from patient B, which were acquired under ADT, affected only 82 genes ( Figure 1B ; see the Materials and methods section). This is in stark contrast to the two CRPC populations in patient D that resulted from a punctual evolution with 599 and 1554 genes affected by genomic CNAs (see below). We next investigated androgen receptor (AR) gene amplification as a known mechanism for CRPC. The AR gene was amplified in five out of the seven patients: the copy number levels varied from duplication in the diploid population of patient A to multiple folds (log 2 ratio = 2.1) in one of the aneuploid populations of patient C ( Figure 1C ). Analysis of this CRPC tissue specimen revealed the co-existence of an adenocarcinoma (AC) and a neuroendocrine (NE) cancer component. Genomic profiling based on aCGH of these two different compartments revealed a clonal relationship with shared as well as private genomic aberrations: The AC cells, but not the NE cells, showed AR gene amplification (supplementary material, Figure S2 ). This is in line with the current understanding that NE differentiation is a mechanism of castration resistance circumventing the AR signalling pathway [29, 30] . The liver metastasis of the same patient was genomically more closely related to the NE than to the AC compartment (0.58 versus 0.64 Pearson's rho), suggesting the NE compartment as the origin of the liver metastasis. This was further exemplified by specific genomic aberrations, such as the homozygous deletion of the RB1 gene, which was only shared between the liver metastasis and the NE compartment of the primary tumour (supplementary material, Figure S2 ). This is in line with recent findings showing that RB1 alterations are a hallmark of NE carcinomas in general [31] .
We next focused on the rate of CNAs acquired under the selective pressure of ADT and the underlying evolutionary models. In line with conventional evolutionary theory, our observed patterns fitted the two concepts of gradualism and punctualism described in 1977 [27] . The evolution of virtually all tumours in this study (six out of seven; Table 1 and Figure 1A -C) can be attributed to the first model since CNAs were acquired in small and gradual steps. In contrast, in patient D, ADT resulted in two distinct aneuploid CR populations (3.6 N and 6.0 N), both having massive rearrangements of chromosome 12 that were not present in the preceding HN 3.6 N aneuploid population. This suggests that a punctual event consistent with chromothripsis must have occurred after initiation of ADT (star in Figure 1D ), leading to massive rearrangements within this chromosome.
Analysis of the different populations arising from chromothripsis identifies FKBP4 as a potential driver
To determine the potential role of chromothripsis as a selective event for progression to castration resistance, we next focused on the genomic profiles of the two tumour populations in the CRPC specimen of patient D. Chromothripsis involves the shattering of one or a few chromosomes in a single event, resulting in a large number of CNAs and massive intrachromosomal rearrangements [32] . In these two co-occurring aneuploid populations, chromothripsis affected only chromosome 12, in particular the whole p-arm and about 30 Mb of the q-arm (Figure 2A) . CNAs in the remaining chromosome regions were mostly shared by the two populations, although not entirely. For example, the 6 N population contained a unique deletion spanning 35 Mb at the beginning of chromosome 4, which was not present in the 3.6 N population. A remarkable amount of differently sized amplifications and deletions was detected in the chromothriptic region. A total of 361 genes were affected by CNAs in this region (3.6 N: 212; 6 N: 134). As the chromothriptic regions show significant differences between the samples, only 30% (81) and 24% (23) of the 265 amplified and 96 deleted genes, respectively, were shared by both populations ( Figure 2B and supplementary material, Figure S3 ). Whole-exome sequencing revealed 12 interchromosomal structural rearrangements (supplementary material, Figure S4 ) but also a total of 69 intrachromosomal rearrangements on the chromosome region affected by the chromothripsis: 27 for the 3.6 N population and 42 for the 6 N population ( Figure 2C ). None of these intrachromosomal structural variants, which are likely products of chromothripsis, were shared between the two aneuploid populations. These findings suggest that the two aneuploid CRPC populations did not originate from each other but evolved in parallel from a common ancestor that had undergone chromothripsis. The 3.6 N HN PC population from 2005 is likely to be this common ancestor since the CNAs in its genome were still present in the two 2010 aneuploid CRPC populations. Accordingly, both of the later CRPC tumour populations showed the same correlation coefficient as the putative common ancestor population (Pearson's rho = 0.58; supplementary material, Figure S5 ). Analysis of the AR amplicon shows different breakpoints and amplicon sizes for the 3.6 N and 6 N populations and therefore does not support synchronous development (supplementary material, Figure S6 ). It is debatable if chromothripsis may be a selective driver event and not just a bystander process [33] . We thus hypothesised that these two aneuploid CRPC populations were selected due to a common genomic aberration providing them with a selective advantage under the ADT environment. We interrogated the genome for aberrant segments with highly deviant log 2 ratios (> 2 from baseline 0) in both of the aneuploid CRPC populations (2010) and with low absolute log 2 ratio differences between the two populations ( Figure 3A) . Based on our hypothesis, we selected for genes with a reported function in CR or steroid pathway signalling: We identified FKBP4 as the most promising candidate and verified its genomic and expression status by FISH and IHC (Figures 3 and 4) . Of note, FKBP4 (also known as FKBP52) is considered to be part of the AR complex and has been identified as an enhancer of AR function [34] [35] [36] [37] . As expected, FISH analysis with an FKBP4-specific probe revealed genomic amplification in the CRPC tissue biopsy from 2010 but normal gene status in the HNPC tissue from 2005 ( Figure 4) . The CRPC, but not the HNPC, was positive for FKBP4 by immunohistochemistry, suggesting that FKBP4 gene amplification emerging from chromothripsis might be the underlying mechanism for high protein expression.
FKBP4 is highly expressed in a subset of hormone-naïve prostate cancer and associated with poor overall survival
To further define a potential role for FKBP4 in progression to castration resistance and its association with androgen signalling, we performed in vitro cell growth experiments. We selected the benign prostate cell line BPH-1, due to its intact androgen axis, to study androgen-related effects in PC [38] . BPH-1 cells were grown in androgen-depleted medium and transfected with either an FKBP4 cDNA overexpressing plasmid under a CMV promoter or shRNA encoding plasmids aimed towards the silencing of FKBP4 (supplementary material, Figure S8 ). Both conditions were evaluated with and without exogenous addition of testosterone (70 nM) and assessed using real-time impedance measurements. Silencing and overexpression of FKBP4 in BPH-1 resulted in reduced and increased proliferation, respectively, of these cells in testosterone-supplemented medium ( Figure 5A, B) . We next investigated the role of FKBP4 amplification and protein expression in a larger cohort of human prostate cancers. For this purpose, we determined the gene copy number and protein level of FKBP4 by FISH and IHC, respectively, on the crTMA. This tissue microarray consists of 114 HNPC and 117 CRPC formalin-fixed and paraffin-embedded tumour specimens. It was specifically constructed for the analysis of markers in the progression of HN to CRPC [8, 15, 39, 40] . Copy number status was evaluable in 198 of 231 cases. We detected genomic amplification of FKBP4 in 4 of 98 HN (4%) and in 2 of 100 CRPC (2%) samples (supplementary material, Figure  S9 ). Polysomy was found in another four HN (4%) and eight CRPC samples (8%). Immunohistochemistry revealed that 77/110 (71%) HN and 95/114 (84%) CRPC samples expressed FKBP4 (histoscore >0). Analysis of the matched HN/CRPC cohort showed an increase of at least ten histoscore units in FKBP4 protein in 50% (n = 11) of the 22 evaluable cases from HN to CR but a decrease in only 14% (n = 3). Although we observed a trend towards higher FKBP4 expression in PC samples with increased FKBP4 gene copy numbers (amplification or polysomy), tumours with normal FKBP4 gene copy number could also sustain high FKBP4 levels of up to 300 histoscore units, suggesting that other mechanisms besides amplification can lead to high FKBP4 protein expression. In contrast to the above-mentioned results of patient D, there was no general increase in FKBP4 protein in the CRPC versus HNPC samples on this TMA.
We speculated that this could be due to the advanced stage of the HNPC cohort of this crTMA since the samples were mostly from palliative transurethral resections of the prostate (TUR-P). Thus, we investigated FKBP4 protein levels on a second prostate TMA that was constructed for the general analysis of markers in the different PC stages, including 535 tumour and control samples ranging from incidentally detected localised PC to advanced metastatic CRPC [41] . Indeed, on this TMA, FKBP4 protein expression was increased in CRPC in comparison to HNPC ( Figure 5C ), with a mean FKBP4 histoscore of 14.4 for the HN and 87.1 for the CR samples (Wilcoxon rank-sum test: p = 2.301e-07). Since FKBP4 has been described as a co-activator of the AR, we investigated a potential correlation of FKBP4 protein with AR and AR phosphorylation (serine 210-phosphorylated AR: pAR SER210 ). We used pAR SER210 data that had been acquired on the crTMA for a previous study [15] . While no association was observed with total levels of AR, we detected a positive association between FKBP4 expression and pAR SER210 in HNPC (Spearman's rho = 0.385, p = 0.013) and in CRPC (Spearman's rho = 0.468, p = 0.0005), emphasising the potential role of FKBP4 under hormone withdrawal to sustain AR pathway signalling ( Figure 5D, E) . Since the AR is known to activate kallikrein-related peptidase 3 (KLK-3) gene expression, encoding prostate-specific antigen (PSA), we further investigated a correlation between PSA values in the blood and FKBP4 protein on the crTMA. Indeed, increased FKBP4 protein was associated with higher blood PSA levels in CRPC but not in HNPC (Spearman's rho = 0.33, p = 0.022) (supplementary material, Figure S10 ). We next investigated the potential impact of FKBP4 on overall survival. Survival analysis (median follow-up time for HN and CRPC was 36.6 and 8.4 months, respectively) revealed a strong association between high FKBP4 protein expression (grouped by median histoscore) and poor overall survival in HN patients (χ 2 = 22.4, n = 80, p = 8.59e-07) ( Figure 5F ). The survival rate at median follow-up time (33 months) was 79% and 38% for patients with low and high FKBP4 protein expression, respectively. This association was not observed in the CR population (χ 2 = 0.1, n = 73, p = 0.735). describing the genomic landscape of PC [42] or applying mathematical modelling for determining clonality based on allelic frequencies [43] . Even though such computational approaches to capture tumour heterogeneity show impressive advances, they rely on model assumptions, which might not cover the whole complexity of human cancers and their evolution under treatment over time [44] [45] [46] . We selected patients with multiple longitudinal biopsies, including at least one obtained under ADT. Time intervals of up to 9 years and the availability of fresh-frozen material allowing DNA content-based flow-sorting before genomic profiling were essential for this study. We identified different patterns of tumour evolution highlighting the heterogeneity of PC and the pressure of ADT during selection for CR tumour cell populations.
Comparisons between tumour evolution and evolution of species in the context of conventional evolution theory have been made previously [9] . Classically, evolution has been divided into punctual and gradual events [27] , which have both been cited in the context of PC evolution [28] . We tracked the evolution of82 JR Federer-Gsponer et al adenocarcinoma HN population via different mechanisms: (i) androgen sensitisation through genomic amplification of the AR gene, and (ii) bypassing of the AR pathway via neuroendocrine differentiation. We have demonstrated that mechanisms for escaping ADT are not mutually exclusive, but can occur concurrently within the same tumour. Interestingly, one of our seven patients showed chromothripsis as an extreme case of punctuated evolution. Although it has been reported that 5-6% of PCs show signs of chromothripsis [47, 48] , to the best of our knowledge, this is the first time that chromothripsis has been shown in the context of progression to CRPC. Of note, the biopsy affected by chromothripsis showed a normal p53 protein expression by immunohistochemistry, arguing against a p53 mutation (supplementary material, Figure S7 ). This is in contrast to reports in other tumour entities [49, 50] , where chromothripsis has been linked to TP53 gene mutation. The co-existence of two distinct populations with chromothripsis escaping ADT towards CRPC in a single tumour specimen provides strong evidence for a selective advantage [33] . It is unlikely that the different copy number profiles in the different tumour populations could have been discovered by genomic analyses of bulk material, i.e. without prior purification by the use of flow sorting.
Several mechanisms have been proposed for the development of chromothripsis [33, 51] . Our results indicate two distinct genomics patterns arising from chromothripsis in one single tissue specimen and provide important new insights into the elucidation of this phenomenon. The sequential generation of one chromothriptic population from the other is rather unlikely and advocates that both populations must have resulted from a single catastrophic event. One might speculate that even more populations emerged under the premise of high genomic instability, but that only the ADT-resistant populations survived. Our data suggest that both populations have been selected independently from each other but that the shared genomic aberrations in the affected chromosome 12 region might have conferred resistance to ADT. The comparative evaluation led to the identification of FKBP4 as a shared amplified candidate gene.
The FKBP4 protein is known as a component of the AR complex that is required for AR's nuclear translocation after ligand binding. FKBP4 has been suggested as a potential therapeutic target in CRPC, and there is a synthetic inhibitor with anti-proliferative effects in androgen-stimulated PC cells in vitro [37, 52] . This concept is in line with our findings showing decreased cell growth after shRNA-based knockdown of FKBP4, as opposed to increased cell proliferation after FKBP4 overexpression. Of note, overexpression was ineffective in stimulating proliferation in the total absence of androgens, suggesting that FKBP4 function depends on remaining low levels of androgens. In fact, FKBP4 might enhance androgen axis function through increased receptor affinity and nuclear translocation [35] and therefore might be able to sustain AR function under ADT. Recently, it has been reported that the interaction of beta-catenin with FKBP4 potentiates hormone-dependent, as well as hormone-independent, AR activity [53] . This further supports the model that FKBP4 amplification and/or overexpression may be a potential mechanism in the progression towards CRPC. Our finding of a significant association between FKBP4 and poor overall survival in advanced hormone-naïve PC patients emphasises a critical role for FKBP4 in advanced PC. Here, for the first time, we have demonstrated the significance of FKBP4 in the context of CR in a large cohort of clinical samples. FKBP4-positive advanced HNPC might be pre-selected and conditioned to resist subsequent ADT, which would explain the poor overall survival in this patient group. Once CR disease has been achieved, the specific mechanism of CR does not affect progression or prognosis.
In contrast to FKBP4, CR mechanisms such as AR amplification and AR mutation appear to be selected for after initiation of ADT, as they are almost never detectable in HNPC. Further studies are needed to clarify if FKBP4 amplification and/or expression can serve as a predictor of poor response to ADT. Interestingly, FKBP4 does not interact with the truncated AR protein resulting from the AR-V7 splice variant, which lacks the ligand binding domain, the site of interaction with FKBP4. In the presence of AR-V7, FKBP4 inhibitors lose their anti-proliferative effect in cell line experiments [36] . According to public databases, amplification of FKBP4 can be detected in up to 3.3% of PCs [54] . This is in line with our detected amplification rates of 2% and 4% in HN and CRPC. Importantly, we have shown high FKBP4 expression in a much larger proportion of our cohort, suggesting that other mechanisms besides gene amplification can lead to increased expression of FKBP4. Our study was not designed to fully elucidate the role of FKBP4 in the context of androgen-driven PC but based on the results of our copy number profiling, we identified FKBP4 as a promising candidate biomarker to better predict the response to ADT and as a potential therapeutic target to be tested in future studies. Figure S1 . Illustration of patients E-G analogues of Figure 1 . All patient samples following a gradual pattern of evolution 
SUPPLEMENTARY MATERIAL ONLINE
